Colorado Just Got Permission to Buy Its Drugs From Canada

The logistics are more complex than "buy drugs in Canada, sell them in Colorado." There's a full chain of custody that reads like an international relay race.

First, an FDA-approved Foreign Seller (a company called AdiraMedica, based in Canada) purchases eligible drugs directly from manufacturers. Those drugs ship to AdiraMedica's U.S. subsidiary in Pennsylvania, which serves as the official importer. From there, every batch goes to Q Laboratories for testing: identity, strength, purity, the works.

Only after the lab confirms everything checks out do the drugs get relabeled with FDA-compliant U.S. packaging. New labels, new NDC codes, new patient information inserts. Then, and only then, the medications ship to participating Colorado pharmacies for dispensing.

It's thorough. It's bureaucratic. And that's kind of the point; the entire program is designed to answer the industry's biggest objection before it can be raised.

PhRMA Is Not Taking This Quietly

Speaking of the industry's objections, they are loud and plentiful.

PhRMA, the pharmaceutical industry's powerful trade group, has called similar importation approvals "reckless" and warned of "life-threatening consequences." The organization filed citizen petitions urging FDA to reject Colorado's proposal, arguing that importation undermines supply chain safety and opens the door to counterfeit or substandard medications.

When Florida got its authorization in January 2024, PhRMA said it was "considering all options" to stop implementation. Legal challenges are widely expected for Colorado's program too, following the same playbook: lawsuits against the underlying federal rule, procedural challenges, and a steady drumbeat of public safety messaging.

Colorado's health department has fired back, accusing the industry of using the citizen petition process to delay FDA review and spreading what it called "disinformation" about the program's safety.

This fight is far from over.

The Canada Problem Nobody Wants to Talk About

There's an even bigger obstacle than PhRMA, and it sits about 2,000 miles north.

Canada doesn't want to be America's pharmacy. Ottawa has maintained export restrictions since November 2020, prohibiting distribution outside Canada of any drug whose export could cause or worsen a shortage. And the math makes the concern obvious: Canada's population is roughly one-eighth the size of America's. One study estimated that if the U.S. imported just 46 commonly used Canadian drugs, Canadian stocks of most would be depleted in under three months.

When Colorado approached 23 manufacturers in 2024 to participate in the program, only four agreed to even take a meeting. None agreed to supply drugs. Florida's program, authorized over two years ago, still hasn't imported a single pill, partly because of pushback from the Canadian pharmaceutical industry.

Canada's health minister has told U.S. officials that Canada "will take all necessary measures to protect the Canadian drug supply." That's diplomat-speak for "don't count on us."

Why This Still Matters

So if the drugs might never actually arrive, why does any of this matter?

Because the precedent is the product. Colorado's authorization proves the regulatory pathway works. It shows that states can navigate the FDA's Section 804 process and come out the other side with a stamp of approval.

The real pressure here isn't on Canadian suppliers; it's on U.S. drug manufacturers. Every state that gets authorization is another reminder that the political will to challenge American drug prices isn't going away. The threat of importation may ultimately do more to bring prices down than importation itself.

Colorado's program projects average per-drug price reductions of 60 to 65 percent compared to current U.S. prices. Even if manufacturers eventually find ways to block the supply chain, those numbers become a talking point in every pricing negotiation, every legislative hearing, and every election cycle.

The FDA just handed Colorado a permission slip. Whether it becomes a prescription depends on battles that are only getting started, in courtrooms, in Ottawa, and in the boardrooms of some of the world's most powerful companies.

Grab the popcorn. This one's going to take a while.

Adaptive Biotech Is Breaking Up With Itself

Adaptive Biotechnologies is splitting its profitable cancer diagnostics business from its early-stage drug discovery platform into two separate companies. The move follows a growing industry trend of corporate breakups designed to let fundamentally different businesses attract the right investors.